drugset / Trial / NCT04675762
Combinating Fingolimod With Alteplase Bridging With Thrombectomy in Acute Ischemic Stroke
Phase 2
Unknown
118 enrolled
Second Affiliated Hospital, School of Medicine, Zhejiang University
Affiliated Hospital of Jiaxing University · collabHuizhou Municipal Central Hospital · collabJinhua Center Hospital · collabShaoxing People's Hospital · collabTaizhou Hospital · collabThe Second Affiliated Hospital of Jiaxing University · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Proof-of concept clinical trials have indicated that the sphingosine-1-phosphate receptor modulator fingolimod may be efficacious in attenuating brain inflammation and improving clinical outcomes in patients with AIS as a single therapy beyond 4.5 hours of disease onset, or in combination with alteplase within 4.5 hours of disease onset. So in this study the investigators try to determine whether the addition of fingolimod, administered within 24 hours after the onset of symptoms in patients receiving alteplase bridging with mechanical thrombectomy, improves radiologic and clinical outcomes.
Timeline
- Start
- 2021-01-15
- Primary completion
- 2025-12-15
- Completion
- 2026-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fingolimod | Small molecule | 0.5 mg | — |